TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:- Confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus by pathologist.~* Endoscopic ultrasound or CT evidence of tumor penetration through the esophageal wall or involvement of regional lymph nodes, without evidence of distant metastasis~* No prior chest radiation therapy~* No prior chemotherapy for esophageal cancer~* Age greater than 18 years~* No infections requiring antibiotic treatment~* Able to care for self~* Patients must have acceptable liver, kidney and bone marrow function.~* The effects of the chemotherapy drugs on the developing human fetus are unknown. Women of child-bearing potential and men must agree to use adequate contraception. Exclusion Criteria:- Patients receiving any other investigational agents~* Evidence of distant metastases~* Uncontrolled medical illness~* Any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.~* Pregnant and breastfeeding women are excluded.~* HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Abortion IUD & Recurrent Abortion 2005-2006

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female resident of Interior Health region seeking an abortion between January 1, 2005 and December 31, 2006~Exclusion Criteria:~* Women undergoing abortions for fetal genetic abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IUD (Type: None): Repeat abortion rate in women receiving IUDs immediately post-abortion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bronchitis and Emphysema Advice and Training to Reduce Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Population to be studied~The study population consists of VA patients with COPD who receive some of their medical care at Veterans Affairs medical centers and were hospitalized for COPD in the last 12 months. To ensure that patients enrolled in the study receive regular care at the participating VA, we will include only patients enrolled in either the primary care or pulmonary clinic at the VA medical center and were seen at least once in the last year. This criterion should not significantly decrease the number of eligible patients because 90% of patients admitted for COPD in the VA had at least 1 outpatient visit to the VA primary care clinic in the year prior to their hospitalization based on data from the VA OPC in FY03.~Inclusion Criteria:~1. Diagnosis of COPD confirmed by all of the following:~   1. FEV1/FVC \< 0.70~  2. FEV1 \< 80%~  3. Age \> 40 years~  4. A current or past history of cigarette smoking (\> 10 pack-years)~2. COPD hospitalization in the previous year~3. Receives care at participating VA medical center~   1. Enrolled in either primary care or pulmonary clinic at the VA~  2. Seen at least once in the past year in either primary care or pulmonary clinic~4. No COPD exacerbations in last 4 weeks~5. English-speaking~6. Access to telephone~Exclusion Criteria:~1. Primary clinical diagnosis of asthma~2. Medical conditions affecting the ability to participate in the study such as:~   1. Comorbid illness likely to limit life expectancy \< 1 year~  2. Decompensated heart failure~  3. Dementia~  4. Uncontrolled psychiatric illness~3. Participation in another clinical intervention trial in the previous 30 days

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: NO_INTERVENTION): Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
- Group 2 (Type: EXPERIMENTAL): The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Recovery Strategies in Elective Breast Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to and greater than 18 years.~* Medically cleared to undergo elective breast surgery (including associated anesthesia) at UW Transformations Surgery Center or Madison Surgery Center (MSC).~* Undergoing bilateral breast augmentation or bilateral breast reduction by the PI (Dr. Venkat Rao).~Exclusion Criteria:~* Minors or under the age of 18~* Pregnant or breast feeding women~* Incarcerated women~* Males~* Individuals unable to give consent due to another condition such as impaired decision-making capacity.~* Women who take opioid pain medications on a regular basis prior to surgery.~* Women with a history of opioid abuse and/or dependence.~* Women who, based on anesthesiologist discretion, are not candidates for paravertebral block.~* Women with BMI \>35~* Women with a diagnosis of obstructive sleep apnea who are noncompliant with their treatment (e.g. CPAP use).~* Women with a history of bleeding disorders precluding safe paravertebral block.~* Women on anticoagulation therapy who have not held their anticoagulation as recommended by their surgeon or anesthesiologist.~* Women with a history of infection at the site of paravertebral block.~* Women not medically cleared for surgery at Transformations or MSC and thus would not be undergoing surgery at Transformations or MSC. This would include women with sepsis/bacteremia, significant valvular disorders or heart conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 Arm A (Type: EXPERIMENTAL): Breast reduction with Paravertebral block using local anesthetic.
- Group 1 Arm B (Type: SHAM_COMPARATOR): Breast reduction with Sham paravertebral block using saline.
- Group 2 Arm A (Type: EXPERIMENTAL): Breast augmentation with Paravertebral block using local anesthetic.
- Group 2 Arm B (Type: SHAM_COMPARATOR): Breast augmentation with Sham paravertebral block using saline.
- Group 3 Arm A (Type: EXPERIMENTAL): Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
- Group 3 Arm B (Type: NO_INTERVENTION): Breast reduction, standard perioperative management.
- Group 4 Arm A (Type: EXPERIMENTAL): Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
- Group 4 Arm B (Type: NO_INTERVENTION): Breast augmentation, standard perioperative management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* SCLC or PAC that is advanced or has spread to other parts of the body~* Treated with at least one other chemotherapy that did not work or where cancer relapsed~* Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1~Exclusion Criteria:~* Patients with cancer that spread to the brain~* Active, known or suspected autoimmune disease~* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC) (Type: ACTIVE_COMPARATOR): Small cell lung cancer (SCLC)
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC) (Type: ACTIVE_COMPARATOR): Pancreatic cancer (PAC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Basiliximab Maintenance in Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously met eligibility criteria in the previous basiliximab UC study~2. Must have a total Mayo score at entry consistent with clinical response or clinical remission.~3. Signed a current IRB/IEC-approved informed consent form~4. Females of childbearing potential must use an effective birth control method, and be willing to continue birth control during the study, and for 4 months after the last dose of study drug.~5. Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months before study entry, hysterectomy, or bilateral oophorectomy at least 2 months before study entry) or post-menopausal for at least 2 years.~Exclusion Criteria:~1. Subject is severely ill, as evidenced by more than 6 episodes of loose stools, all of them bloody, during a 24-hour period within the prior 7 days, concurrent with any of the following systemic features:~   * Heart rate \> 90 beats/min at rest~  * Temperature \> 37.8 degrees C~  * Hemoglobin \< 10.5 g/dL~2. Subject is currently receiving a restricted/prohibited concomitant medication~3. Subject has undergone colectomy (total, or subtotal)~4. Subject is pregnant or breast-feeding~5. Prior noncompliance with previous study visit schedule and requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Regional Erector Spinae Analgesic Block vs Standard of Care Undergoing Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥ 18 years Undergoing unilateral or bilateral PCNL for treatment of kidney stones Estimated glomerular filtration rate \> 30 mL/min. PCNL is planned as an outpatient procedure with no overnight hospital stay~Exclusion Criteria:~Inability to provide informed consent Pregnancy Patients having any additional simultaneous procedures other than a contralateral PCNL,(including contralateral treatment of kidney stones with a non-PCNL operation such as ureteroscopy) Patients with a documented neurologic injury that reduces pain sensation to the back Patients with an existing pain disorder Patients with an existing narcotics agreement due to current or prior narcotic abuse Patients with a documented allergy to a narcotic or NSAID analgesic BMI \> 35 Patients who require more than 1 site of percutaneous access into the kidney to adequately complete the PCNL (this is a judgment made preoperatively at the initial clinic patient encounter)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: OTHER): Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
- ANES Block (Type: EXPERIMENTAL): Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: APPROPRIATE - Rate Adaptive Pacing Sensor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets or met current pacemaker implantation indications~* Willing and capable of providing informed consent for participation~* Receiving a dual-chamber pacemaker or previously received a dual-chamber pacemaker with active atrial and ventricular leads~* Plans to remain in the long-term care of his/her enrolling physician and is available for study follow-up for three months post-enrollment~Exclusion Criteria:~* Mobitz II second degree heart block~* Third degree heart block~* Chronic atrial fibrillation or uncontrolled atrial arrhythmias within the past 90 days prior to consent~* Neuromuscular, orthopedic, or vascular disability that prevents normal walking or weight carrying (e.g., intermittent claudication, arthritis, residual stroke weakness, need for a wheelchair or walker)~* A symptom-limited exercise protocol is thought to be dangerous or contra-indicated, including but not limited to changing pattern of chest discomfort or uncontrolled arrhythmias~* Pulmonary disease as defined by any one of the following:~  * Forced Vital Capacity (FVC) or Forced Expiratory Volume in one second (FEV1) \< 60% of predicted values~ * Use of two or more pulmonary inhalers~ * Use of supplemental oxygen~ * Chronic use of oral steroids for pulmonary disease treatment~* Life expectancy is less than 12 months due to other medical conditions, per physician discretion~* Has or indicated for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)~* Currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study.~* Younger than 18 years of age~* Pregnant or planning to become pregnant during the study (method of assessment upon physician's discretion)~* Unable or unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accelerometer (Type: ACTIVE_COMPARATOR): Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
- Minute Ventilation (Type: ACTIVE_COMPARATOR): Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extracellular Fluid in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* BP \>140/85~* 3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)~Exclusion Criteria:~* Pregnancy~* Breast Feeding~* Unstable heart failure~* Chronic Liver Disease~* Creatinine \>120 mcmol/L~* Contraindication to (or intolerance of) drug used in study~* BP \> 180/110

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 40-85 years of age~* Women must be post menopausal (absence of menses for 12 months or greater)~* 25-hydroxyvitamin D level below 20 ng/ml (50 nmol/L)~* BMI 25-45 kg/m2~* Non smoker ( non smoking for at least 12 months:cigarettes, cigars, pipes)~Exclusion Criteria:~* Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (BP over 180 mm HG) unless medically stabilized~* Currently being treated for active cancer~* Type 1 diabetes; insulin treatment for diabetes, poorly controlled diabetes, HgA1c \>10%~* Allergic to lidocaine~* History of seizures or taking anti-seizure or anti convulsion medications~* Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)~* Taking oral steroids, warfarin or other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (ie for 72 hours prior)~* Taking medication that interfere with ability to replete Vitamin D~* Abnormal liver function 2 times normal levels~* Abnormal renal function (BUN above 40 mg/dl, Cr above 1.8 mg/dl, CrCl\<60mg/dl)~* Hypercalcemia (Ca\>10.2mg/dl)~* Anemia HCT below 30 mg/dl, platelets below 100,000/cm3~* Chronic pulmonary disease (on supplemental O2)~* Other systemic disorders that are not medically treated and stable or affect the ability to absorb Vitamin D.~* MMSE below 24, dementia or unstable clinical depression by exam~* Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120 mm HG, or other contraindications to exercise) \*requires follow up treatment w/ primary MD for continued participation in study~* Aerobically trained with VO2max greater than 2 SD above age-adjusted mean~* Participant is, in the opinion of the investigator, unable to adhere to the study protocol due to medical or orthopedic conditions that limit ability to exercise or travel to the Baltimore VA for protocol procedures.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- RDA Vitamin D (Type: ACTIVE_COMPARATOR): None
- Vit D repletion + 6M Supplementation (Type: EXPERIMENTAL): None
- Vit D repletion + 6M Supplementation +AEX (Type: EXPERIMENTAL): None
- Vit D repletion + 6M Supplementation +RT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diathermy Compared With Sham Diathermy in Doms Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy patients who complaints about D.O.M.S. after a skimountaneering race~Exclusion Criteria:~- Patient who complain of pathology such trauma or declaring consuming drugs for pain management where excluded from the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Switched on diathermy (Type: ACTIVE_COMPARATOR): Switched on diathermy was used on DOMS compared to sham diathermy
- Switched OFF diathermy (Type: SHAM_COMPARATOR): Switched OFF diathermy was used on DOMS compared to REAL diathermy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility